Is there a pharmacodynamic need for the use of continuous versus intermittent infusion with ceftazidime against Pseudomonas aeruginosa? An in vitro …
L Alou, L Aguilar, D Sevillano… - Journal of …, 2005 - academic.oup.com
Objectives: In order to explore the pharmacodynamic need for continuous versus intermittent
(three times a day) administration of ceftazidime in critically ill patients, a pharmacokinetic …
(three times a day) administration of ceftazidime in critically ill patients, a pharmacokinetic …
Is there a pharmacodynamic need for the use of continuous versus intermittent infusion with ceftazidime against Pseudomonas aeruginosa? An in vitro …
L Alou, L Aguilar, D Sevillano… - The Journal of …, 2005 - pubmed.ncbi.nlm.nih.gov
Objectives In order to explore the pharmacodynamic need for continuous versus intermittent
(three times a day) administration of ceftazidime in critically ill patients, a pharmacokinetic …
(three times a day) administration of ceftazidime in critically ill patients, a pharmacokinetic …
Is there a pharmacodynamic need for the use of continuous versus intermittent infusion with ceftazidime against Pseudomonas aeruginosa? An in vitro …
L Alou, L Aguilar, D Sevillano, MJ Giménez… - The Journal of …, 2005 - europepmc.org
Objectives In order to explore the pharmacodynamic need for continuous versus intermittent
(three times a day) administration of ceftazidime in critically ill patients, a pharmacokinetic …
(three times a day) administration of ceftazidime in critically ill patients, a pharmacokinetic …
[引用][C] Is there a pharmacodynamic need for the use of continuous versus intermittent infusion with ceftazidime against Pseudomonas aeruginosa? An in vitro …
L Alou, L Aguilar, D Sevillano… - Journal of …, 2005 - portalcientifico.universidadeuropea …
Objectives: In order to explore the pharmacodynamic need for continuous versus intermittent
(three times a day) administration of ceftazidime in critically ill patients, a pharmacokinetic …
(three times a day) administration of ceftazidime in critically ill patients, a pharmacokinetic …
[PDF][PDF] Is there a pharmacodynamic need for the use of continuous versus intermittent infusion with ceftazidime against Pseudomonas aeruginosa? An in vitro …
L Alou, L Aguilar, D Sevillano, MJ Giménez… - researchgate.net
Objectives: In order to explore the pharmacodynamic need for continuous versus intermittent
(three times a day) administration of ceftazidime in critically ill patients, a pharmacokinetic …
(three times a day) administration of ceftazidime in critically ill patients, a pharmacokinetic …
[PDF][PDF] Is there a pharmacodynamic need for the use of continuous versus intermittent infusion with ceftazidime against Pseudomonas aeruginosa? An in vitro …
L Alou, L Aguilar, D Sevillano, MJ Giménez… - Journal of …, 2005 - academia.edu
Objectives: In order to explore the pharmacodynamic need for continuous versus intermittent
(three times a day) administration of ceftazidime in critically ill patients, a pharmacokinetic …
(three times a day) administration of ceftazidime in critically ill patients, a pharmacokinetic …
Is there a pharmacodynamic need for the use of continuous versus intermittent infusion with ceftazidime against Pseudomonas aeruginosa? An in vitro …
L Alou, L Aguilar, D Sevillano, MJ Gimenez… - Journal of Antimicrobial …, 2005 - elibrary.ru
Objectives: In order to explore the pharmacodynamic need for continuous versus intermittent
(three times a day) administration of ceftazidime in critically ill patients, a pharmacokinetic …
(three times a day) administration of ceftazidime in critically ill patients, a pharmacokinetic …
[引用][C] Is there a pharmacodynamic need for the use of continuous versus intermittent infusion with ceftazidime against Pseudomonas aeruginosa? An in vitro …
L ALOU, L AGUILAR, D SEVILLANO… - Journal of …, 2005 - pascal-francis.inist.fr
Is there a pharmacodynamic need for the use of continuous versus intermittent infusion with
ceftazidime against Pseudomonas aeruginosa? An in vitro pharmacodynamic model CNRS …
ceftazidime against Pseudomonas aeruginosa? An in vitro pharmacodynamic model CNRS …
[PDF][PDF] Is there a pharmacodynamic need for the use of continuous versus intermittent infusion with ceftazidime against Pseudomonas aeruginosa? An in vitro …
L Alou, L Aguilar, D Sevillano, MJ Giménez… - Journal of Antimicrobial …, 2005 - Citeseer
Objectives: In order to explore the pharmacodynamic need for continuous versus intermittent
(three times a day) administration of ceftazidime in critically ill patients, a pharmacokinetic …
(three times a day) administration of ceftazidime in critically ill patients, a pharmacokinetic …
[PDF][PDF] Is there a pharmacodynamic need for the use of continuous versus intermittent infusion with ceftazidime against Pseudomonas aeruginosa? An in vitro …
L Alou, L Aguilar, D Sevillano, MJ Giménez… - Citeseer
Objectives: In order to explore the pharmacodynamic need for continuous versus intermittent
(three times a day) administration of ceftazidime in critically ill patients, a pharmacokinetic …
(three times a day) administration of ceftazidime in critically ill patients, a pharmacokinetic …